Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€162.90

€162.90

1.840%
2.95
1.840%
€120.00
 
20:28 / Tradegate WKN: 659990 / Symbol: MKGAF / Name: Merck / Stock / Pharmaceuticals / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Merck KGaA Stock

Merck KGaA gained 1.840% today.
The community is currently still undecided about Merck KGaA with 1 Buy predictions and 1 Sell predictions.
This results in a negative potential of -26.34% based on a current price of 162.9 € and a target price of 120 € for the stock.
For the coming years our community has positive and negative things to say abot the Merck KGaA stock. Criterium "Return on equity" gathered the most positive votes but regarding "Expected dividend yield" there were negative voices in the community.

Pros and Cons of Merck KGaA in the next few years

Pros
?
G***** c******* t* c**********
?
S********** s********
?
B****
Cons
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Merck KGaA vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Merck KGaA 1.840% 1.847% 1.427% -7.757% 11.115% 9.555% 60.689%
Bayer AG -0.370% 8.048% -2.110% -49.181% -15.215% -46.693% -49.780%
Pfizer Inc. 0.580% 1.181% 3.421% -31.025% -1.533% -16.191% -27.515%
Elanco Animal Health Inc. 1.230% 0.946% -1.581% 77.350% 10.503% -36.722% -

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-15

It appears that Merck, operating under the US symbol MKGAF, showcases stable financial performance within the pharmaceuticals industry. The company has shown consistent growth in total assets and net income in recent years, and its overall financial position and liquidity seem to be in good shape.

In conclusion, Merck's financials reveal a generally positive situation for the company, with growth in total assets, net income, and operating cash flows. However, certain areas, such as increased long-term debt, negative net tangible assets, and changes in net working capital necessitate careful monitoring. As an analyst, monitoring Merck's financial performance and management strategies will be crucial to ensure sustained growth and stability in the coming years.

Comments

Buy Merck KGaA
Show more

Buy Merck KGaA
Show more

Sell Merck KGaA
Show more

News

2 Monster Stocks to Buy Without Any Hesitation: https://g.foolcdn.com/editorial/images/765695/physician-giving-a-high-five-to-a-young-patient.jpg
2 Monster Stocks to Buy Without Any Hesitation

Investing in stocks is a great way for most people to grow their wealth over time. However, all stocks aren't created equal. Some are unlikely to deliver anything resembling solid returns over the

Here's Why Merck, Eli Lilly, and Novo Nordisk Stocks Rose 11% Last Month: https://g.foolcdn.com/editorial/images/764656/gettyimages-663845678-600x400-bf06395.jpg
Here's Why Merck, Eli Lilly, and Novo Nordisk Stocks Rose 11% Last Month

January was a big month for pharmaceutical stocks, with Merck (NYSE: MRK), Eli Lilly (NYSE: LLY), and Novo Nordisk (NYSE: NVO) all climbing 11%, according to data provided by S&P Global Market

3 companies that more than doubled analyst EPS estimates: https://www.marketbeat.com/logos/articles/med_20240204125241_chart-luv.jpg
3 companies that more than doubled analyst EPS estimates

Earnings season is well underway, and the winner-and-loser separation continues to grow. Of the companies that beat consensus analyst estimates, even fewer go well beyond and exceed analyst